People · Operator
Named in public records as an officer, director or promoter · active 2014–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ventus Therapeutics U.S., Inc. | — | Biotechnology | Series C | $186.8M | $1.6B | 2022 |
| Kolltan Pharmaceuticals Inc | — | Biotechnology | Series C | $137.0M | $2.5B | 2014 |
| Ophthotech Corp. | — | Biotechnology | Series B | $43.1M | $452.5M | 2018 |
Jane Pritchett Henderson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jane Pritchett Henderson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Axel Bolte | 2 | 6 |
| Michael Ross | 1 | 18 |
| Jerel Davis | 1 | 13 |
| David Guyer | 1 | 8 |
| Josh Resnick | 1 | 7 |
| Peter Hirth | 1 | 7 |
| Hao Wu | 1 | 5 |
| Thomas Dyrberg | 1 | 5 |
| John Cassidy | 1 | 3 |
| Markus Warmuth | 1 | 3 |
| E. Jonathan Soderstrom | 1 | 3 |
| Nicholas C. Galakatos | 1 | 3 |
| Thomas B Neff | 1 | 3 |
| Steven James | 1 | 3 |
| Gerald McMahon | 1 | 3 |
| Michael C. Ross | 1 | 3 |
| Daniel Koerwer | 1 | 2 |
| W. Bradford Middlekauff | 1 | 2 |
| Michael Schmertzler | 1 | 2 |
| K. Peter Hirth | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.